-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEG-irinotecan in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEG-irinotecan in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEG-irinotecan in Glioblastoma Multiforme (GBM) Drug Details: PEG-Irinotecan is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NTX-303 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NTX-303 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NTX-303 in Solid Tumor Drug Details: NTX-303 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RNK-05047 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RNK-05047 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RNK-05047 in Diffuse Large B-Cell Lymphoma Drug Details:RNK-05047 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RNK-05047 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RNK-05047 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RNK-05047 in Solid Tumor Drug Details:RNK-05047 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-442257 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-442257 in Marginal Zone B-cell Lymphoma Drug Details: SAR-442257 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RNK-05047
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RNK-05047 Drug Details RNK-05047 is under development for the treatment of advanced solid tumor...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. The Bromodomain-containing protein 4 - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Bromodomain-containing protein 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration...